NEW YORK–(Small business WIRE)–Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one particular of the biggest totally integrated operators in the international health-related cannabis business with licenses across the US and EU, announced that it has entered into an exclusive agreement with Moeller Pharma GmbH (“Moeller”), a GMP-certified German producer of higher-high quality herbal extracts, functional beverages and plant-derived mixture supplements for the pharmaceutical and meals industries, to create a portfolio of proprietary cannabinoid-infused items to be sold globally, starting with Europe and the US.

Moeller has been a trusted name in German households for a lot more than 75 years, nicely recognized for the production and distribution of more than 100 various higher-high quality fruit juices, plant-primarily based functional drinks, supplements and other items sold by means of its established network of wellness meals retailers, drug retailers and hypermarkets in Europe. Via its relationships with six of the biggest German wholesalers, Moeller has access to more than 22,000 independent pharmacies and retailers in Germany alone and presently produces a lot more than 72 one of a kind extracts and distillates of medicinal plants at scale for major pharmaceutical firms. Moeller also possesses substantial production capacity, presently extracting a lot more than 600 metric tons of biomass per year at its state-of-the-art, FDA authorized, Excellent Manufacturing Practice (GMP) certified facility in Germany.

Beneath the terms of the agreement, Columbia Care will contribute its GMP/GAP industrial hemp biomass, chemistry and extraction experience as nicely as its cannabinoid extraction capabilities for use in wellness and wellness items when Moeller will present its library of plant-primarily based extracts, mixture items, manufacturing capabilities, distribution channels and expertise in generating well-known functional customer items for the international pharmaceutical, wellness and meals markets. The parties will exclusively collaborate on study and improvement (R&D) efforts to create a one of a kind, patentable portfolio of cannabinoid-infused wellness and wellness items. Completed items will be manufactured beneath GMP circumstances at Moeller’s German manufacturing facility.

“We operate in a international business and continually appear for techniques to effectively innovate and leverage current, cannabis and non- cannabis provide and distribution chains. Our partnership with Moeller Pharma gives Columbia Care with access to one particular of the most formidable libraries of plant-primarily based wellness and wellness items in Europe as nicely as verified manufacturing and distribution infrastructure that has been inspected and authorized by regulators, which includes in the US. This will let us to navigate the regulatory and efficiency limitations we presently expertise in the US, when nevertheless providing us access to the US market place by means of our network of licenses,” mentioned Nicholas Vita, chief executive officer of Columbia Care. “Creating extended term, sustainable worth by means of item innovation, distribution and income diversification and international expansion that involves importation into the US, are essential elements to Columbia Care’s extended-term development method, and this exclusive arrangement positions us to provide on all 3. Moeller is a trusted, hugely respected international supplement and wellness meals brand deemed amongst the highest finish of the wellness and wellness marketplace, especially in the EU. This strategic collaboration positions us to develop into the US by means of each the cannabis and non- cannabis distribution channels by bringing new plant-primarily based items to the US and the rest of the globe. By combining our current proprietary, pharmaceutical-high quality cannabis-primarily based formulations, extraction capabilities and chemistry experience with Moeller’s current portfolio of customer items, one of a kind library of plant primarily based extracts and supplements and higher-high quality manufacturing approaches, we appear to expedite the improvement, manufacture and distribution of new, market place major items that can be sold globally, supporting new and current Columbia Care and Moeller customers’ need to reside a all-natural, healthful life-style.”

Oliver Hennemann, chief operating officer of Moeller Pharma mentioned, “Columbia Care’s scientific method and concentrate on the patient’s requires has convinced us that it is just the ideal companion to develop our experience in building revolutionary cannabis items.” Hennemann continued saying, “Columbia Care’s deep experience in cannabis item formulation and Moeller’s industrial scale EU GMP extraction and manufacturing capabilities are a best match for good results in this swiftly developing international market place.”

About Columbia Care Inc.

Columbia Care Inc. is one particular of the biggest and most knowledgeable multi-state operators in the health-related cannabis business, with licenses in 15 jurisdictions in the US and the EU. With more than 1.two million sales transactions considering that its inception, Columbia Care is a patient-centered organization setting the common for compassion, professionalism, high quality, caring and innovation, operating in collaboration with some of the most renowned and revolutionary teaching hospitals and health-related centers in the globe. The Business is committed to supplying the variety of education and transparency sufferers deserve and high quality of item that clinicians count on. For a lot more data on Columbia Care, please visit

Caution Regarding Forward-Seeking Statements

This press release consists of specific statements that constitute forward-seeking data inside the which means of applicable securities laws (“forward-seeking statements”). Statements regarding Columbia Care Inc.’s (“Columbia Care” or the “Company”) objectives, targets, techniques, priorities, intentions, plans, beliefs, expectations and estimates, and the company, operations, monetary functionality and situation of Columbia Care are forward-seeking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “may”, “will”, “would”, “could”, “should”, “continue”, “plan”, “goal”, “objective”, and comparable expressions and the unfavorable of such expressions are intended to recognize forward-seeking statements, though not all forward-seeking statements include these identifying words.

Specific material things and assumptions have been applied in supplying these forward-seeking statements. Forward-seeking data entails many assumptions which includes the following precise assumptions: the capacity of Columbia Care to meet its dispensary targets which includes the capacity to negotiate added lease arrangements satisfactory to the corporation, receipt of essential permits and regulatory approvals, timely completion of planned building, and the capacity to recognize and attract certified employees. Projections may perhaps be impacted by macroeconomic things, in addition to other things not controllable by the Business. Columbia Care has also produced specific basic business assumptions in the preparation of such forward-seeking statements. Management believes that the expectations reflected in forward-seeking statements are primarily based upon affordable assumptions on the other hand, Management can give no assurance that actual final results will be constant with these forward-seeking statements. Not all things which impact the forward-seeking data are recognized, and actual final results may perhaps differ from the projected final results in a material respect and may perhaps be above or under the forward-seeking data presented in a material respect.

Forward-seeking statements involve recognized and unknown dangers, uncertainties and other things that may perhaps trigger Columbia Care’ actual final results, functionality or achievements, or developments in its business, to differ materially from the anticipated final results, functionality, achievements or developments expressed or implied by such forward-seeking statements. Provided these uncertainties, readers are cautioned not to location undue reliance on such forward-seeking statements. When thinking about these forward-seeking statements, readers must maintain in thoughts the danger things and other cautionary statements in Columbia Care’s final prospectus dated March 21, 2019 (the “Prospectus”) and filed with the applicable Canadian securities regulatory authorities on SEDAR at The danger things and other things noted in the Prospectus could trigger actual events or final results to differ materially from these described in any forward-seeking data. Forward-seeking statements are primarily based on management’s present plans, estimates, projections, beliefs and opinions, and Columbia Care does not undertake any obligation to update forward-seeking statements must assumptions connected to these plans, estimates, projections, beliefs and opinions transform except as expected by applicable securities laws. All of the forward-seeking statements produced in this press release are certified by these cautionary statements and other cautionary statements or things contained herein, and there can be no assurance that the actual final results or developments will be realized or, even if substantially realized, that they will have the anticipated consequences to, or effects on, Columbia Care.

Get Genuine-Time Updates from The Each day Marijuana Observer







s.parentNode.insertBefore(t,s)}(window, document,'script',


fbq('init', '1208884129216896')

fbq('track', 'PageView')